ema glp-1 vision loss recommendation 2025 Drug Can Cause Rare, Potentially Blinding Side Effect, Warns Warning about sharp rise in

Chen, C.-S

Ozeki et al (2022) found that GLP1-RA semaglutide effectively reduces body adiposity while maintaining the skeletal muscle mass in obese Type 2 Diabetic patients. Xiang et al (2023) had similar findings, semaglutide can reduce the weight and fat of obese patients while effectively maintaining muscle mass and muscle strength. Chen et al (2023) conducted a 3-month intervention using dulaglutide in patients with Type 2 Diabetes, noting , dulaglutide intervention does not cause muscle and bone mass loss while inducing weight loss, and % change in body fat was independently associated with improved glucose control during dulaglutide therapy. With an increasing number of physicians and researchers relying on GLP-1 therapies for clinical care and research, it will continue to be crucial to track sensitive changes in body composition across different patient populations

Dai WL, et al

0.46 g 0.32 g

I feel great, she tells PEOPLE

This early conditioning can contribute to long-term unhealthy eating habits, increasing the risk of obesity and related metabolic dysfunction